Difference between revisions of "Melphalan (Alkeran)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information")
 
(36 intermediate revisions by 3 users not shown)
Line 1: Line 1:
 
==General information==
 
==General information==
−
Class/mechanism: Nitrogen mustard, alkylator.  Melphalan is a bischloroethylamine alkylating agent that crosslinks DNA by binding at the N7 position of guanine, with activity against resting and proliferating cells.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/014691s029lbl.pdf Melphalan (Alkeran) package insert]</ref><ref>[[Media:Melphalan.pdf|Melphalan (Alkeran) package insert (locally hosted backup)]]</ref>
+
Class/mechanism: Nitrogen mustard, alkylator.  Melphalan is a bischloroethylamine alkylating agent that crosslinks DNA by binding at the N7 position of guanine, with activity against resting and proliferating cells.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/014691s029lbl.pdf Melphalan (Alkeran) package insert]</ref><ref>[[:File:Melphalan.pdf|Melphalan (Alkeran) package insert (locally hosted backup)]]</ref>
 
<br>Route: IV, PO
 
<br>Route: IV, PO
 
<br>Extravasation: [[irritant]] or [[neutral]], depending on reference
 
<br>Extravasation: [[irritant]] or [[neutral]], depending on reference
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref>  
 +
 
 +
==Diseases for which it is established ''(work in progress)''==
 +
*[[Peripheral T-cell lymphoma]]
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
 +
*[[Acute myeloid leukemia]]
 
*[[Acute promyelocytic leukemia]]
 
*[[Acute promyelocytic leukemia]]
−
*[[Bone cancer]]
+
*[[Ewing sarcoma]]
−
*[[Hodgkin lymphoma]]
+
*[[Classical Hodgkin lymphoma]]
−
*[[Light-chain (AL) amyloidosis]]
+
*[[Neuroblastoma]]
−
*[[Multiple myeloma]]
+
*Non-Hodgkin lymphoma
−
*[[Plasma cell leukemia]]
+
**[[CNS lymphoma]]
−
*[[Transplant conditioning regimens]]
+
**[[Diffuse large B-cell lymphoma]]
 +
**[[Follicular lymphoma]]
 +
**[[HIV-associated lymphoma]]
 +
**[[Mantle cell lymphoma]]
 +
*Plasma cell dyscrasia
 +
**[[Light-chain (AL) amyloidosis]]
 +
**[[Multiple myeloma]]
 +
**[[Plasma cell leukemia]]
 +
 
 +
==Diseases for which it was used==
 +
*[[Breast cancer - historical|Breast cancer]]
 +
*[[Ovarian cancer - historical|Ovarian cancer]]
  
 
==Patient drug information==
 
==Patient drug information==
−
*[http://chemocare.com/chemotherapy/drug-info/Melphalan.aspx Melphalan (Alkeran) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/Melphalan.aspx Melphalan (Alkeran) patient drug information (Chemocare)]</ref>
+
*[https://chemocare.com/druginfo/Melphalan.aspx Melphalan (Alkeran) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/Melphalan.aspx Melphalan (Alkeran) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/melphalan-patient-drug-information Melphalan (Alkeran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/melphalan-patient-drug-information Melphalan (Alkeran) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/melphalan-patient-drug-information Melphalan (Alkeran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/melphalan-patient-drug-information Melphalan (Alkeran) patient drug information (UpToDate)]</ref>
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
*1/17/1964: Initial FDA approval<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=014691&DrugName=ALKERAN&ActiveIngred=MELPHALAN&SponsorApplicant=GLAXOSMITHKLINE&ProductMktStatus=1&goto=Search.Label_ApprovalHistory Melphalan (Alkeran) FDA approval history]</ref>
+
*1964-01-17: Initial FDA approval<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=014691&DrugName=ALKERAN&ActiveIngred=MELPHALAN&SponsorApplicant=GLAXOSMITHKLINE&ProductMktStatus=1&goto=Search.Label_ApprovalHistory Melphalan (Alkeran) FDA approval history]</ref>
−
 
+
*Uncertain date: Indicated for the palliative treatment of [[multiple myeloma]]. ''(Based on SWG01)''
 +
*Uncertain date: Indicated for the palliation of non-resectable [[Ovarian_cancer|epithelial carcinoma of the ovary]]. ''(No supporting studies are cited)''
 +
==History of changes in EMA indication==
 +
*1963-09-26: EURD
 
==Also known as==
 
==Also known as==
−
Precise Name: Melphalan hydrochloride (RXCUI 235857)
+
*'''Generic names:''' L-PAM, L-Sacrolysin, L-Sarcolysin, MPL, phenylalanine mustard
−
 
+
*'''Brand names:''' Alkeran, Alkerana, Evomela, Levofolan, Melfalan, Phelinun
−
{| border="1" style="text-align:center;"
 
−
!colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms'''
 
−
|-
 
−
|Alkerana
 
−
|L-PAM
 
−
|L-Sacrolysin
 
−
|L-Sarcolysin
 
−
|Levofolan
 
−
|Melfalan
 
−
|}
 
  
 
==References==
 
==References==
 
<references/>
 
<references/>
  
−
[[Category:Drug index]]
+
[[Category:Drugs]]
−
[[Category:Chemotherapy]]
+
[[Category:Intravenous medications]]
−
[[Category:Intravenous chemotherapy]]
+
[[Category:Oral medications]]
−
[[Category:Irritant chemotherapy]]
+
 
−
[[Category:Neutral chemotherapy]]
+
[[Category:Irritant]]
−
[[Category:Oral chemotherapy]]
+
[[Category:Neutral]]
  
 
[[Category:Alkylating agents]]
 
[[Category:Alkylating agents]]
 
[[Category:Nitrogen mustards]]
 
[[Category:Nitrogen mustards]]
  
 +
[[Category:Acute myeloid leukemia medications]]
 
[[Category:Acute promyelocytic leukemia medications]]
 
[[Category:Acute promyelocytic leukemia medications]]
−
[[Category:Bone cancer medications]]  
+
[[Category:CNS lymphoma medications]]
−
[[Category:Hodgkin lymphoma medications]]
+
[[Category:Diffuse large B-cell lymphoma medications]]
 +
[[Category:Ewing sarcoma medications]]
 +
[[Category:Follicular lymphoma medications]]
 +
[[Category:HIV-associated lymphoma medications]]
 +
[[Category:Classical Hodgkin lymphoma medications]]
 
[[Category:Light-chain (AL) amyloidosis medications]]
 
[[Category:Light-chain (AL) amyloidosis medications]]
 +
[[Category:Mantle cell lymphoma medications]]
 
[[Category:Multiple myeloma medications]]
 
[[Category:Multiple myeloma medications]]
 +
[[Category:Neuroblastoma medications]]
 +
[[Category:Peripheral T-cell lymphoma medications]]
 
[[Category:Plasma cell leukemia medications]]
 
[[Category:Plasma cell leukemia medications]]
−
[[Category:Transplant medications]]
 
  
−
[[Category:Drugs FDA approved in 1964]]
+
[[Category:Breast cancer medications (historic)]]
 +
[[Category:Ovarian cancer medications (historic)]]
 +
 
 +
[[Category:FDA approved in 1964]]
 +
[[Category:EMA approved in 1963]]
 +
[[Category:WHO Essential Cancer Medicine]]

Latest revision as of 01:04, 29 June 2024

General information

Class/mechanism: Nitrogen mustard, alkylator. Melphalan is a bischloroethylamine alkylating agent that crosslinks DNA by binding at the N7 position of guanine, with activity against resting and proliferating cells.[1][2]
Route: IV, PO
Extravasation: irritant or neutral, depending on reference

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

  • 1964-01-17: Initial FDA approval[5]
  • Uncertain date: Indicated for the palliative treatment of multiple myeloma. (Based on SWG01)
  • Uncertain date: Indicated for the palliation of non-resectable epithelial carcinoma of the ovary. (No supporting studies are cited)

History of changes in EMA indication

  • 1963-09-26: EURD

Also known as

  • Generic names: L-PAM, L-Sacrolysin, L-Sarcolysin, MPL, phenylalanine mustard
  • Brand names: Alkeran, Alkerana, Evomela, Levofolan, Melfalan, Phelinun

References

  1. ↑ 1.0 1.1 Melphalan (Alkeran) package insert
  2. ↑ Melphalan (Alkeran) package insert (locally hosted backup)
  3. ↑ Melphalan (Alkeran) patient drug information (Chemocare)
  4. ↑ Melphalan (Alkeran) patient drug information (UpToDate)
  5. ↑ Melphalan (Alkeran) FDA approval history
Retrieved from "https://hemonc.org/w/index.php?title=Melphalan_(Alkeran)&oldid=87341"